Condition: Neuropathology · Sponsor: University Hospital, Montpellier
Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides and the deterioration of sleep, but current knowledge does not confirmed this link. The objective of this study is to define whether there is a link between cognitive decline and sleep disorders. If a correlation is found, this could allow earlier treatment of sleep disorders in the longer term in order to slow the development of AD.
This description comes directly from the study's public registry record.
Claire Denis · +33467333162 · claire-denis@chu-montpellier.fr
Yves Dauvilliers, MD · +33467335219 · y-dauvilliers@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| University Hospital, Montpellier | Montpellier, France | Recruiting |
| University Hospital of Poitiers | Poitiers, France | Not Yet Recruiting |
| University Hospital of Toulouse | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05629871